AddThis

Dr. Reddy's launches generic osteoporosis drug

Drug maker announces launch of generic version of Novartis' Reclast

HYDERABAD, India — Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

The drug, launched following its approval by the Food and Drug Administration, is a generic version of Novartis' Reclast and is used to treat osteoporosis. Reclast had sales of $355 million during the 12-month period that ended in February, according to IMS Health.

The launch follows last month's launch of zoledronic acid injection in the 4-mg-per-5-mL, a generic version of Novartis' Zometa, which is another version of the drug used to treat the cancer multiple myeloma and cancers that have spread to the bones.

CORRECTION: An earlier version of this story misstated the strength of Dr. Reddy's generic version of Zometa. The story has been corrected.

Osteoporosis is common to

Osteoporosis is common to aging person and can not be treated easily because medicines is too expensive for this kind of illness, but with this new development hope it the poor has now an alternative for the expensive one. - The Balancing Act Lifetime

© 2014 Drug Store News. All Rights Reserved.